Key facts
- It has raised $64.3M; the latest was Early Stage VC ($42.0M) in Jul 2025.
- Notable investors include Tech Incubator Program for Startup, Korea Development Bank, IMM Investment, Hana Ventures, STIC Ventures — 27 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 27 names
- ·Watchlist + deal alerts for Illimis Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Illimis Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Illimis Therapeutics
Developer of protein-based therapeutics designed for the treatment of intractable neurodegenerative diseases. The company's platform leverages proprietary protein engineering and molecular design techniques, enabling the biopharmaceutical companies to increase drug candidates with target specificity and improved stability.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2021
- Employees
- 40
- Website
- illimistx.com/
- Ownership
- Privately Held (backing)
Illimis Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Illimis Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Illimis Therapeutics in its N-PORT filings yet. We sweep new filings monthly.